Table 1 Clinical metadata and on-chip metabolic cytometry data of LADC patients^a

From: Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics

No.	Age range	Histology^b	Stage	Driver mutations detected by OMC	Driver mutations in cell blocks^c	Survival (months)^d	PE volume (mL)	2-NBDG^High/C12R^Low	2-NBDG^Low/C12R^High	2-NBDG^High /C12R^High
1	71–80	ADC	IV	EGFR ^19Del	EGFR ^19Del	20.6 (alive)	22	20	42	4
2	51–60	ADC	IV	EGFR^E19-A750P + EGFR^19Del	Wild type	19.6 (alive)	4.9	11	10	9
3	61–70	ADC	IV	EGFR ^L858R	EGFR ^L858R	15.6	47.6	36	15	0
4	71–80	ADC	IV	KRAS ^G12C	KRAS ^G12C	0.8	40	125	18	5
5	41–50	ADC	IV	EGFR ^L858R	NA (Lung: EGFR^L858R)	7.13	80	8	7	1
6	71–80	ADC	IV	EGFR ^19Del	EGFR ^19Del	9.1	3.9	22	31	1
7	41–50	ADC	IV	EGFR ^L858R	NA (Lung: EGFR^L858R)	10.1	11.7	34	10	3
8	81–90	ADC	IV	EGFR^E19-A750P + EGFR^19Del	EGFR ^19Del	7.03	3.9	51	20	1
9	81–90	ADC	IV	EGFR ^19Del	EGFR ^19Del	1.93	2.8	35	7	2
10	41–50	ADC	IV	EGFR ^19Del	EGFR ^19Del	15.2 (alive)	10.8	9	59	17
11	61–70	ADC	IV	EGFR ^L858R	EGFR ^L858R	7.23	83.3	12	9	2
12	61–70	ADC	IV	EGFR^19Del + EGFR^T790M	EGFR^19Del + EGFR^T790M	4.03	75	31	9	3
13	41–50	ADC	IV	EGFR ^19Del	EGFR ^19Del	16.0 (alive)	50	10	12	6
14	81–90	ADC	IV	Wild type	Wild type	7.13	16.7	19	14	1
15	31–40	ADC	IV	ALK	NA (Lung: ALK)	15.9 (alive)	2	16	46	24
16	41–50	ADC	IV	ROS1	ROS1	2.43	11.2	26	2	18
17	61–70	ADC	IV	EGFR ^19Del	EGFR ^19Del	14.8 (alive)	117	3	19	1
18	51–60	ADC	IV	EGFR ^19Del	EGFR ^19Del	20.0 (alive)	8	12	11	3
19	51–60	ADC	IV	EGFR ^L858R	NA (Lung: EGFR^L858R)	17.7 (alive)	50	8	9	0
20	71–80	ADC	IV	Wild type	Wild type	3.03	40	27	7	10
21	71–80	Diagnosis undetermined		Wild type	Wild type	3.03	68	20	167	12
22	61–70	ADC	IV	Wild type	Wild type	15.4 (alive)	16	15	10	2
23	61–70	ADC	IV	Wild type	Wild type	10.3	90	11	7	7
24	61–70	ADC	IV	Wild type	Wild type	5.93	2.2	33	17	18
25	41–50	ADC	IV	Wildtype	Wild type	14.3 (alive)	0.5	26	22	9
26	51–60	ADC	IV	EGFR^L858R + EGFR^T790M	EGFR^L858R + EGFR^T790M	14.3 (alive)	18.8	10	10	1
27	41–50	ADC	IV	ALK	ALK	5.5	12.5	299	95	23
28	41–50	ADC	IV	EGFR ^19Del	EGFR ^19Del	5.9 (alive)	0.3	37	48	15
29	71–80	ADC	IV	Wild type	Wild type	5.9 (alive)	5	23	11	6
30	71–80	ADC	IV	KRAS ^G12C	KRAS ^G12C	3.6	0.9	127	27	20
31	41–50	ADC	IV	EGFR ^L858R	EGFR ^L858R	1.3	3	63	12	5
32	51–60	ADC	IV	KRAS ^G12C	KRAS ^G12C	NA^e	1.5	35	914	15

^aIn all 32 patients involved in this study, 19 (59.375%) of them are male. cytological analysis failed to identify malignant cells in PE samples of four patients (P5, P21, P22, and P23), but OMC detected candidate metabolically active tumor cells. P5, P22, and P23 were diagnosed based on the biopsies of the primary tumors. However, for P21, biopsy of the lung lesion was clinically high-risk and not performed because of the advanced age of the patient and the small size of primary lesion, leading to an inconclusive diagnosis. The last three columns of the table denote numbers of CD45^neg, metabolically active cells per 500,000 input cells from PE samples
^bKey for histology: ADC, lung adenocarcinoma
^cMutations and detection methods of cell blocks from MPE samples: EGFR (ARMS), ALK (IHC), ROS1 (RT-PCR);
^dThe survival time was calculated from the time that pleural effusion was drawn and measured
^eThis patient was most recently enrolled in this study and treatment-naïve

Back to article page

Table 1 Clinical metadata and on-chip metabolic cytometry data of LADC patients^a

Search

Quick links